Biopharma | May 05, 2026
Zydus Lifesciences subsidiary faces Rs 9 million GST demand notice
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
He has been associated with the Zydus Group since 2009
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Subscribe To Our Newsletter & Stay Updated
